



# Laboratory Response to a KPC Outbreak at the NIH Clinical Center

Anna Lau<sup>1\*</sup>, Stella Antonara<sup>1</sup>, Frida Stock<sup>1</sup>, Tara Palmore<sup>2</sup>, Adrian Zelazny<sup>1</sup>

<sup>1</sup>Microbiology Service, Department of Laboratory Medicine; <sup>2</sup>Hospital Epidemiology Service, Clinical Center, National Institutes of Health, Bethesda, MD, US

Control number: #3618

Contact information: ASM 2012  
 Anna Lau (PhD)  
 Tel: 301-496-4433  
 Fax: 301-402-1886  
 Anna.Lau@nih.gov

## INTRODUCTION

*Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* (KPC-KP) are notorious nosocomial pathogens that are resistant to nearly all antimicrobials and can rapidly develop further resistance upon exposure to the remaining active agents.

Resistance is caused by the enzyme-encoding KPC gene that is carried on a plasmid transmissible among the Enterobacteriaceae. The KPCs comprise 10 variants (KPC<sub>2-11</sub>) that are uniquely characterized by single nucleotide substitutions<sup>1</sup>.


The epidemiological challenge of KPC-KP along with high attributable mortality (40-60%) has prompted heavy investment on infection control and preventive measures.

Between June to December 2011, the NIH Clinical Center experienced its first KPC-KP outbreak in the ICU. Prompt laboratory response was crucial for hospital epidemiological guidance and limiting the spread of disease.

## ACKNOWLEDGEMENTS

We would like to acknowledge all the microbiology staff & HES at the NIH CC

## OUTBREAK TIMELINE



## LABORATORY RESPONSE

**6/29:**  
 - Two rounds of throat & groin surveillance cxs initiated. Subbed onto SBA & MAC  
 - Any GNR was identified by MALDI-TOF MS  
 - Full susceptibility testing performed  
 - Carbapenemase activity confirmed by MHT

**8/5:**  
 - Weekly throat & groin surveillance cxs initiated in ICU and later on other wards  
 - SBA & MAC proved inefficient  
 - Evaluation of KPC Chromagar against CDC protocol  
 - Rectal swabs added to surveillance cultures to increase sensitivity

**8/15:**  
 - KPC Chromagar implemented for throat, groin & rectal surveillance cxs  
 - Identification confirmed by MALDI-TOF MS  
 - Full susceptibility testing performed  
 - Carbapenemase activity confirmed by MHT

**9/15:**  
 KPC PCR developed for colonies

**9/1 to 1/20/12**  
 Environmental cultures detected KPC-KP from 5 environmental sites (patient room, ventilator & 3 sink drains) and KPC-E. cloacae from 2 drain cxs

**9/30:**  
 Outbreak strain Whole Genome Sequencing (*Snrkin et al, pers com*)

**10/30:**  
 - Evaluation & validation of a KPC Taqman PCR to detect blaKPC directly from rectal swabs  
 - Implemented into routine diagnostic use 1/17/12

**Table 1. Isolation Source of KPC-KP**

Pt #	Date	Specimen	Site	Outcome	Notes
1	06/13/11	Rectal	ICU	Alive	
2	06/13/11	Rectal	ICU	Alive	
3	06/13/11	Rectal	ICU	Alive	
4	06/29/11	Rectal	ICU	Alive	
5	08/05/11	Rectal	ICU	Alive	
6	08/23/11	Rectal	ICU	Alive	
7	09/15/11	Rectal	ICU	Alive	
8	09/19/11	Rectal	ICU	Alive	
9	09/22/11	Rectal	ICU	Alive	
10	10/06/11	Rectal	ICU	Alive	
11	10/17/11	Rectal	ICU	Alive	
12	10/17/11	Rectal	ICU	Alive	
13	11/03/11	Rectal	ICU	Alive	
14	11/10/11	Rectal	ICU	Alive	
15	11/17/11	Rectal	ICU	Alive	
16	11/18/11	Rectal	ICU	Alive	
17	11/27/11	Rectal	ICU	Alive	
18	12/14/11	Rectal	ICU	Alive	

**Clinical isolates:** 13 (72%) Total pts (18), 10 (91%) Died (11), 4 (50%) Alive (8)

**Surveillance cxs only:** 5 (28%), 1 (9%) Died (11), 4 (50%) Alive (8)

**DATA SUMMARY**  
 A total of 602 pts were screen between 6/2011 & 1/2012 (674 throat, 699 groin & 1,333 rectal)

KPC-KP was isolated from 18 pts  
 - 5 (28%) were colonized only  
 - 13 (72%) developed KPC-KP infections  
 - 8 (62%) were bloodstream infections  
 - 5 were co-colonized/infected with MDRAB  
 - 1 was co-infected with KPC-E. cloacae  
 - 1 was co-infected with KPC-E. aerogenes

11 pts died (overall mortality 61%)  
 - 7 from KPC-KP infection (attributable mortality 39%)

>95% similarity was established between all KPC-KP isolates by rep-PCR (Aligent)

**KPC Chromagar Validation**  
 KPC Chromagar (Paris) was tested in parallel with the CDC Laboratory Protocol for the "Detection of Carbapenem-Resistant or Carbapenemase Producing *Klebsiella* or *E. coli* from Rectal Swabs"

**KPC PCR Development & Validation**  
 - A real-PCR assay was developed to detect a 246bp region of the bla<sub>KPC</sub> gene (inclusive bla<sub>KPC2-11</sub>) using primers and probes described by Hindiyeh et al<sup>2</sup>

- DNA was extracted from one rectal swab using the NucleiSense easyMag system (BioMerieux)

- The assay was validated in parallel with KPC Chromagar using 60 rectal swabs

- Assay correlation efficiency was 1. No cross reactivity was observed with human DNA, stool flora or other carbapenem resistant non-KPC organisms (eg. MDRAB)

1. Ladder; 2. KPC-KP Pt #1; 3. MDRAB; 4. E. coli; 5. K. pneumoniae; 6. K. pneumoniae ATCC 3705; 6. K. pneumoniae ATCC 1706; and 7. No DNA control

**KPC RESPONSE ALGORITHM**  
 Following this outbreak and the changes implemented, we have developed the following algorithm for laboratories to respond to future KPC outbreaks

**REFERENCES**  
 1. Chen L et al. Multiple real-time PCR assay for detection and classification of *Klebsiella pneumoniae* carbapenemase gene (bla<sub>KPC</sub>) variants. JCM 2011; 49(2):579-85.  
 2. Hindiyeh M et al. Rapid detection of bla<sub>KPC</sub> carbapenemase genes by real-time PCR. JCM 2008; 46(9):2879-81.